Factitiously Elevated Total Triiodothyronine in a Euthyroid Patient with Multiple Myeloma

Table 1

Summary of laboratory results.

TFTs	Roche Cobas kit, 08/28/19	Siemens Atellica kit, 10/25/20	Siemens Atellica kit, 10/26/20	Roche Cobas kit 11/17/20
TSH	0.750 (0.27–4.2 uIU/mL)	6.27 (0.55–4.78 uIU/mL)	4.84 (0.55–4.78 uIU/mL)	1.82 (0.27–4.2 IU/mL)
FT4		1.22 (0.89–1.76 ng/dL)	1.28 (0.89–1.76 ng/dL)
TT4	7.6 (4.5–12.0 μg/dL)	4.5 (3.2–12.6 μg/dL)	4.7 (3.2–12.6 μg/dL)
TT3	82 (80–200 ng/dL)	>600 (60–181 ng/dL)	>600 (60–181 ng/dL)	47.4 (80–200 ng/dL)
HAMA			<56 (<74 ng/mL)
TPO ab			<1 (<9 IU/mL)
TG ab			<1 (<1 IU/mL)
TSI			<89 (<140%)
T3 antibody			Negative (Quest/Nichols proprietary test)
Free T3			1.7 (2.3–4.2 pg/mL) (Siemens Advia kit)
Reverse T3			21 (8–25 ng/dL) (Thermo Aria kit)